Neurocrine Biosciences, Inc. announced that Christopher O'Brien, M.D., Chief Medical Officer, has notified the company he plans to retire in February 2018, after a transition period with his successor. Dr. O'Brien will remain as an exclusive consultant for Neurocrine. Eiry W. Roberts, M.D., will join the company as Chief Medical Officer, effective January 8, 2018. Dr. Roberts has over 25 years of research and development experience in the pharmaceutical industry across all phases of drug development from research through commercialization in multiple therapeutic areas, including neuroscience, inflammation, oncology and metabolic diseases. She joins Neurocrine from Eli Lilly and Company where she held various positions during her tenure, including Vice President, Clinical Pharmacology and Vice President of R&D, BioMedicines Business Unit. Dr. Roberts was the Chair of the Medical Review Committee.